

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year)

11 July 2001 (11.07.01)

International application No.

PCT/US00/24129

Applicant's or agent's file reference

06727/010WO2

International filing date (day/month/year)

01 September 2000 (01.09.00)

Priority date (day/month/year)

02 September 1999 (02.09.99)

Applicant

MURGITA, Robert, A. et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

08 March 2001 (08.03.01)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Claudio Borton

Telephone No.: (41-22) 338.83.38

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15709 A1

(51) International Patent Classification⁷: **A61K 31/7088**,
38/38, C12N 5/00, 15/85

Cambridge, MA 02138 (US). LINDSAY, Stace [US/US];
8 Cypress Street, Cambridge, MA 02140 (US).

(21) International Application Number: PCT/US00/24129

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).

(22) International Filing Date:

1 September 2000 (01.09.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/152,166 2 September 1999 (02.09.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/152,166 (CIP)
Filed on 2 September 1999 (02.09.1999)

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(71) Applicant (*for all designated States except US*): ATLANTIC BIOPHARMACEUTICALS, INC. [US/US]; 50 Church Street, Cambridge, MA 02138 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MURGITA, Robert, A. [US/CA]; 17 Parkside Place, Montreal, Quebec H3H 1A7 (CA). MULROY, Robert [US/US]; 19 Hilliard Street,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/15709 A1

(54) Title: USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS

(57) Abstract: A method of inhibiting apoptosis in a cell by administering to the cell an apoptosis inhibiting amount of recombinant human alpha-feta protein or an apoptosis-inhibiting fragment thereof.

INTERNATIONAL SEARCH REPORT

I national application No.
PCT/US00/24129

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/7088, 38/38; C12N 5/00, 15/85
US CL : 435/375, 455; 514/2, 44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/375, 455; 514/2, 44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SEMENKOVA et al. Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumor Biol. 1997, Vol. 18, No. 5, pages 261-273, especially page 264.	1
Y	LADEROUTE et al. Role of AFP and 67 kD AFPr isoforms in the abrogation of apoptosis. Tumor Biol. 1996, Vol. 17, No. Suppl. 1, page 10, see entire document.	1
Y	DUDICH et al. The inhibition of TNF-induced apoptosis by human alpha-fetoprotein. Anticancer Res. 17-22 October 1995, Vol. 15, No. 5A, pages 1728-1729, see entire document.	1



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 DECEMBER 2000

Date of mailing of the international search report

25 JAN 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT SCHWARTZMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/24129

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LADEROUTE et al. The inhibition of apoptosis by alpha-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence. Anticancer Res. November-December 1994, Vol. 14, No. 6B, pages 2429-2438, especially pages 2433-2434.	1
Y	BENNETT et al. Similarity between natural and recombinant alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res. Treat. September 1997, Vol. 45, No. 2, pages 169-179, see entire document.	1, 2
A	PALU et al. In pursuit of new developments for gene therapy of human diseases. J. Biotechnol. 1999, Vol. 68, pages 1-13, see entire document.	1-8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24129

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: Medline, Biosis, Embase, CAPlus

WEST: All databases

Search Terms: alpha-fetoprotein, AFP, apoptosis, programmed cell death

USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS

BACKGROUND OF THE INVENTION

5 The invention related to methods of inhibiting apoptosis.

 There are two general ways in which cells die. The most easily recognized way is by necrosis, which is usually caused by an injury that is severe enough to disrupt cellular homeostasis. Typically, the cell's osmotic pressure is disturbed and, consequently, the cell swells and then ruptures.

10 When the cellular contents are spilled into the surrounding tissue space, an inflammatory response often ensues.

 The second general way by which cells die is referred to as apoptosis, or programmed cell death. Apoptosis often occurs so rapidly that it is difficult to detect. This may help to explain why the involvement of
15 apoptosis in a wide spectrum of biological processes has only recently been recognized.

 The apoptosis pathway has been highly conserved throughout evolution, and plays a critical role in embryonic development, viral pathogenesis, cancer, autoimmune disorders, and neurodegenerative disease.
20 For example, inappropriate apoptosis may cause or contribute to AIDS, Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), retinitis pigmentosa and other diseases of the retina, myelodysplastic syndrome (e.g. aplastic anemia), toxin-induced liver disease, including alcoholism, and ischemic injury (e.g. myocardial infarction, stroke, and
25 reperfusion injury). Conversely, the failure of an apoptosis response has been implicated in the development of cancer, particularly follicular lymphoma, p53-mediated carcinomas, and hormone-dependent tumors, in autoimmune

disorders, such as lupus erythematosus and multiple sclerosis, and in viral infections, including those associated with herpes virus, poxvirus, and adenovirus.

In patients infected with HIV-1, mature CD4⁺ T lymphocytes respond to stimulation from mitogens or super-antigens by undergoing apoptosis. However, the great majority of these cells are not infected with the virus. Thus, inappropriate antigen-induced apoptosis could be responsible for the destruction of this vital part of the immune system in early stages of HIV infection.

SUMMARY OF THE INVENTION

In general, the invention features the inhibition of apoptosis in a cell, e.g., a cell in a mammal such as a human patient, by contacting the cell with recombinant alpha-fetoprotein ("rHuAFP") or an effective fragment thereof, or with nucleic acid encoding rHuAFP. The invention, in inhibiting apoptosis, can provide therapy for diseases in which inappropriate apoptosis is a feature, including AIDS or HIV infection, neurodegenerative diseases such as ALS, a myelodysplastic syndrome, or an ischemic injury such as occurs in stroke, myocardial infarction, reperfusion injury, or a toxin-induced liver disease.

Other features and advantages of the invention will be apparent from the detailed description of the invention, the drawings, and the claims.

BRIEF SUMMARY OF THE DRAWINGS

Fig. 1 is the nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of the cDNA encoding human alpha-fetoprotein, and the amino acid sequences (SEQ ID NOs: 3-8) of rHuAFP fragments.

Fig. 2 is the SDS-PAGE analysis of rHuAFP Fragment I (SEQ ID NO: 8) (Lane A, MW marker; Lane B, native human alpha-fetoprotein (AFP); Lane C, unpurified rAFP; Lane D, rAFP Fragment I, and Lane E, AFP (amino acids 1-590 of Fig. 1, SEQ ID NO: 2).

DETAILED DESCRIPTION OF THE INVENTION

Production of Recombinant Human Alpha-fetoprotein

Recombinant AFP can be produced in any standard recombinant protein production system, including prokaryotic cells such as E. coli, and eukaryotic systems such as yeast, mammalian (e.g., CHO cells) and insect cells.

10 Prokaryotic production of rHuAFP is described in Murgita U.S. Patent No. 5,384,250, hereby incorporated by reference.

The methods of the invention can also employ biologically active fragments of rHuAFP. A biologically active fragment of rHuAFP is one that possesses at least one of the following activities: (a) directs a specific
15 interaction with a target cell, e.g., binds to a cell expressing a receptor that is recognized by rHuAFP (e.g., the membrane of a cancer cell such as MCF-7); or (b) halts, reduces, or inhibits apoptosis (e.g., binds to a cell surface receptor and imparts an anti-apoptosis signal). The ability of rHuAFP fragments to bind to a receptor which is recognized by rHuAFP can be tested using any
20 standard binding assay known in the art.

In general, fragments of rHuAFP are produced according to the techniques of polypeptide expression and purification described in U.S. Patent No. 5,384,250. DNA sequences encoding fragments of rHuAFP can be generated by standard techniques and cloned into expression vectors for
25 expression in recombinant cells. Expressed fragments can be isolated by various chromatographic and/or immunological methods known in the art.

Lysis and fractionation of rHuAFP-containing cells prior to affinity chromatography may be performed by standard methods. Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques In Biochemistry and Molecular Biology, Work and Burdon, eds., Elsevier, 1980).

Recombinant HuAFP fragments can be assayed by immunological procedures, such as Western blot, immunoprecipitation analysis of recombinant cell extracts, or immunofluorescence (using, e.g., the methods described in Ausubel et al., *Current Protocols In Molecular Biology*, Greene Publishing Associates and Wiley Interscience (John Wiley & Sons), New York, 1994).

Useful rHuAFP fragments preferably have at least 20 contiguous amino acids, preferably at least 50 contiguous amino acids, more preferably at least 100 contiguous amino acids, and most preferably at least 200 to 400 or more contiguous amino acids in length.

Recombinant HuAFP fragments of interest include, but are not limited to, Domain I (amino acids 1 (Thr) - 197 (Ser), see Fig. 1, SEQ ID NO: 3), Domain II (amino acids 198(Ser) - 389 (Ser), see Fig. 1, SEQ ID NO: 4), Domain III (amino acids 390 (Gln) - 590 (Val), see Fig. 1, SEQ ID NO: 5), Domain I+II (amino acids 1 (Thr) - 389 (Ser), see Fig. 1, SEQ ID NO: 6), Domain II+III (amino acids 198 (Ser) - 590 (Val), see Fig. 1, SEQ ID NO: 7), and rHuAFP Fragment I (amino acids 266 (Met) - 590 (Val), see Fig. 1, SEQ ID NO: 8).

By "inhibiting apoptosis" is meant a decrease in the number of cells which undergo apoptosis relative to an untreated control. Preferably, the decrease is at least 25%, more preferably the decrease is 50%, and most

preferably the decrease is at least one-fold.

Apoptosis Assays

Apoptosis assays are described in the following references. Assays for apoptosis in lymphocytes are disclosed by, for example: Li et al.,

- 5 "Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein", Science 268:429-431, 1995; Gibellini et al., "Tat-expressing Jurkat cells show an increased resistance to different apoptosis stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection:", Br. J. Haematol. 89:24-33, 1995; Martin et al., "HIV-1 infection of human CD4⁺ T cells *in vitro*.
10 Differential induction of apoptosis in these cells." J. Immunol. 152:330-42, 1994; Terai et al., "Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1", J. Clin Invest. 87:1710-5, 1991; Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) 11, Nature 373:438-441, 1995; Katsikis et al., "Fas antigen stimulation induces
15 marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals", J. Exp. Med. 181:2029-2036, 1995; Estendorp et al., "Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120", Nature 375:497, 1995; DeRossi et al., Virology 198:234-44, 1994.

Assays for apoptosis in fibroblasts are disclosed by, for example:

- 20 Vossbeck et al., "Direct transforming activity of TGF-beta on rat fibroblasts," Int. J. Cancer 61:92-97, 1995; Goruppi et al., "Dissection of c-myc domains involved in S phase induction of NIH3T3 fibroblasts," Oncogene 9:1537-44, 1994; Fernandez et al., "Differential sensitivity of normal and Ha-ras transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction
25 of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells," Oncogene 9:2009-17, 1994; Harrington et al., "c-Myc-induced apoptosis in

fibroblasts is inhibited by specific cytokines," EMBO J., 13:3286-3295, 1994;
Itoh et al., "A novel protein domain required for apoptosis. Mutational
analysis of human Fas antigen," J. Biol. Chem. 268:10932-7, 1993.

Assays for apoptosis in neuronal cells are disclosed by, for example:

- 5 Melino et al., "Tissue transglutaminase and apoptosis: sense and antisense
transfection studies with human neuroblastoma cells," Mol. Cell Biol.
14:6584-6596, 1994; Rosenbaum et al., "evidence for hypoxia-induced,
programmed cell death of cultured neurons," Ann. Neurol. 36:864-870, 1994;
Sato et al., "Neuronal differentiation of PC12 cells as a result of prevention of
10 cell death by bcl-2," J. Neurobiol. 25:1227-1234, 1994; Ferrari et al., "N-
acetylcysteine D- and L-stereoisomers prevents apoptosis death of neuronal
cells," J. Neurosci. 15:2857-2866, 1995; Talley et al., "Tumor necrosis
factor alpha-induced apoptosis in human neuronal cells: protection by the
antioxidant N-acetylcysteine and the genes bcl-2 and crmA," Mol. Cell Biol.
15 1585:2359-2366, 1995; Talley et al., "Tumor Necrosis Factor Alpha-Induced
Apoptosis in Human Neuronal Cells: Protection by the Antioxidant
N-Acetylcysteine and the Genes bcl-2 and crmA," Mol. Cell. Biol. 15:2359-
2366, 1995; and Walkinshaw et al., "Induction of apoptosis in
catecholaminergic PC12 cells by L-DOPA. Implication for the treatment of
20 Parkinson's disease," J. Clin. Invest. 95:2458-2464, 1995.

Assays for apoptosis in insect cells are disclosed by, for example:

- Clem et al., "Prevention of apoptosis by a baculovirus gene during infection of
insect cells," Science 254:1388-90, 1991; Crook et al., "An apoptosis-
inhibiting baculovirus gene with a zinc finger-like motif," J. Virol. 67:2168-
25 74, 1993; Rabizadeh et al., "Expression of the baculovirus p35 gene inhibits
mammalian neural cell death," J. Neurochem. 61:2318-21, 1993; Birnbaum et
al., "an apoptosis inhibiting gene from a nuclear polyhedrosis virus encoding a

polypeptide with Cys/His sequence motifs," J. Virol. 68:2521-8, 1994; and Clem et al., "Control of programmed cell death by the baculovirus genes p35 and IAP," Mol. Cell. Biol. 14:5212-5222, 1994.

Gene Therapy

- 5 rHuAFP-encoding genes can be used according to the invention in anti-apoptosis gene therapy. In particular, a functional rHuAFP gene may be used to sustain neuronal cells that undergo apoptosis in the course of a neurodegenerative disease; lymphocytes (i.e., T cells and B cells); or cells that have been injured by ischemia.
- 10 Retroviral vectors, adenoviral vectors, adeno-associated viral vectors, or other viral vectors with the appropriate tropism for cells likely to be involved in apoptosis (for example, epithelial cells) may be used as a gene transfer delivery system for a therapeutic rHuAFP gene construct. Numerous vectors useful for this purpose are known (Miller, Human Gene Therapy 15-
15 15, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis and Anderson, BioTechniques 6:608-614, 1988; Tolstoshev and Anderson, Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 17:407-416,
20 1991; Miller et al., Biotechniques 7:980-990, 1989; Le Gal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995). Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Patent NO. 5,399,346). Non-viral approaches may also be employed
25 for the introduction of therapeutic DNA into cells otherwise predicted to undergo apoptosis. For example rHuAFP may be introduced into a neuron or a

T cell by lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neurosci. Lett. 117:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989; Staubinger et al., Meth. Enz. 101:512, 1983), asialorosonucoid-polylysine conjugation (Wu et al., J. Biol. Chem. 263:14621, 1988; Wu et al., J. Biol. Chem. 264:16985, 1989); or, less preferably, microinjection under surgical conditions (Wolff et al., Science 247:1465, 1990).

For any of the methods described above, the therapeutic rHuAFP DNA construct is preferably applied to the site of the predicted apoptosis event (for example, by injection), or to tissue in the vicinity of the predicted apoptosis event, or to a blood vessel supplying the cells predicted to undergo apoptosis.

rHuAFP expression can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element. For example, if desired, enhancers that preferentially direct gene expression in neural cells, T cells, or B cells may be used to direct rHuAFP expression. Alternatively, if an rHuAFP genomic clone is used in a therapeutic construct, regulation may be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.

Alternatively, rHuAFP gene therapy is accomplished by direct administration of the rHuAFP mRNA or antisense rHuAFP mRNA to a cell that is expected to undergo apoptosis. The mRNA may be produced and isolated by any standard technique, but is most readily produced by *in vitro* transcription using an rHuAFP cDNA under the control of a high efficiency promoter (e.g., the T7 promoter). Administration of rHuAFP mRNA to cells

can be carried out by any of the methods for direct nucleic acid administration described below.

Ideally, the production of rAFP protein by any gene therapy approach will result in cellular levels of rAFP that are at least equivalent to the normal, cellular level of rHuAFP in an unaffected cell. Treatment by any rHuAFP-mediated gene therapy approach may be combined with more traditional therapies.

Administration of rAFP Polypeptides

Another therapeutic approach of the invention involves administration of recombinant rHuAFP, either directly to the site of a predicted apoptosis event (for example, by injection) or systemically (for example, by any conventional recombinant protein administration technique). The dosage of rHuAFP depends on a number of factors, including the size and health of the individual patient, but, generally, between 0.1 mg and 100 mg are administered per day to an adult in a pharmaceutically-acceptable formulation. Administration may begin before or after the patient is symptomatic. Any appropriate route of administration may be employed, for example, administration may be parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art of making formulations are found, for example, in *Remington's Pharmaceutical Sciences*, (18th edition), ed. A.

Gennaro, 1990, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of rHuAFP.

Treatment with an rHuAFP protein or gene may be combined with more traditional therapies for the disease such as surgery, steroid therapy, or chemotherapy for autoimmune disease; antiviral therapy for AIDS; and tissue plasminogen activator (TPA) for ischemic injury.

Other Embodiments

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

What is claimed is:

1. A method of inhibiting apoptosis in a cell, said method comprising administering to said cell an apoptosis inhibiting amount of rHuAFP or an apoptosis-inhibiting fragment thereof.

2. The method of claim 1, wherein said cell is in a mammal.

5 3. The method of claim 2, wherein said mammal is human.

4. The method of claim 3, wherein said human is infected with HIV, or has a neurodegenerative disease, a myelodysplastic syndrome, or an ischemic injury.

10 5. The method of claim 4, wherein said ischemic injury is caused by a myocardial infarction, a stroke, a reperfusion injury, or a toxin-induced liver disease.

6. A method of inhibiting apoptosis in a cell, said method comprising transfecting said cell with nucleic acid encoding rHuAFP or an apoptosis-inhibiting fragment thereof.

15 7. The method of claim 6, wherein said cell is in a human patient.

8. The method of claim 7, wherein said human patient is infected with HIV, or has a neurodegenerative disease, a myelodysplastic syndrome, or an ischemic injury.

AT (2)
 -1
 met lys trp val glu ser ile phe leu leu asn phe thr glu ser arg
 ATG AAG TGG GTG GAA TCA ATT TTT TTA ATT TTC CTA CTA AAT TTT ACT GAA TCC AGA (101)
 -10
 10
 thr leu his arg asn glu tyr gly ile ala ser ile leu asp ser tyr gln cys thr ala glu ile ser leu ala asp leu ala thr ile
 ACA CTG CAT AGA AAT GAA TAT GGA ATA GGT TCC ATA TTG GAT TCT TAC CAA TGT ACT GCA GAG ATA AGT TTA GCT GAC CTG GCT ACC ATA (191)
 20
 30
 31 phe ala gln phe val gln glu ala thr tyr lys glu val ser lys met val lys asp ala leu thr ala ile glu lys pro thr gly
 TTT TTT GCC CAG TTT GTT CAA GAA GCC ACT TAC AAG GAA GTA AGC AAA ATG CTG AAA GAT GCA TTG ACT GCA ATT GAG AAA CCC ACT GGA (281)
 40
 50
 60
 61 asp glu gln ser ser gly cys leu glu asn gln leu pro ala phe leu glu glu leu lys glu ile leu glu lys tyr gly
 GAT GAA GAG TCT TCA GGG TGT TTA GAA AAC CAG CTA CCT GCC TTT CTG GAA GAA CTT TGC CAT GAG AAA GAA AAT TTG GAG AAG TAC GGA (371)
 70
 80
 90
 91 his ser asp cys cys ser gln ser glu glu gly arg his asn cys phe leu ala his lys lys pro thr pro ala ser ile pro leu phe
 CAT TCA GAC TGC TGC AGC CAA AGT GAA GAG GGA AGA CAT AAC TGT TTT CTT GCA CAC AAA AAG CCC ACT CCA GCA TCG ATC CCA CTT TTC (461)
 100
 110
 120
 121 gln val pro glu pro val thr ser cys glu ala tyr glu glu asp arg glu thr phe met asn lys phe ile tyr glu ile ala arg arg
 CAA GTT CCA GAA CCT GTC ACA AGC TGT GAA GCA TAT GAA GAA GAC AGG GAG ACA TTC ATG AAC AAA TTC ATT TAT GAG ATA GCA AGA AGG (551)
 130
 140
 150
 151 his pro phe leu tyr ala pro thr ile leu leu trp ala ala arg tyr asp lys ile ile pro ser cys lys ala glu asn ala val
 CAT CCC TTC CTG TAT GCA CCT ACA ATT CTT CTT TGG GCT GCT CGC TAT GAC AAA ATA ATT CCA TCT TGC TGC AAA GCT GAA AAT GCA GTT (641)
 160
 170
 180
 181 glu cys phe gln thr lys ala ala thr val thr lys glu leu arg glu ser ser leu leu asn gln his ala cys ala val met lys asn
 GAA TGC TTC CAA ACA AAG GCA GCA ACA GTT ACA AAA GAA TTA AGA GAA AGC AGC TTG TTA AAT CAA CAT GCA TGT GCA GTA ATG AAA AAT (731)
 190
 200
 210

Fig. 1

211 phe gly thr arg thr phe gln ala ile thr val thr lys leu ser gln lys phe thr lys val asn phe thr glu ile gln lys leu val
 TTT GGG ACC CGA ACT TTC CAA GCC ATA ACT GTT ACT AAA CTG AGT CAG AAG TTT ACC AAA GTT AAT TTT ACT GAA ATC CAG AAA CTA GTC (821) 240

 241 leu asp val ala his val his glu his cys cys arg gly asp val leu asp cys leu gln asp gly glu lys ile met ser tyr ise cys
 CTG GAT GTG GCC CAT GTA CAT GAG CAC TGT TGC AGA GGA GAT GTG CTG GAT TGT CTG CAG GAT GGG GAA AAA ATC ATG TCC TAC ATA TGT (911) 270

 271 ser gln gln asp thr leu ser asn lys ile thr glu cys cys lys leu thr thr leu glu arg gly gln cys ile ile his ala glu asn
 TCT CAA CAA GAC ACT CTG TCA AAC AAA ATA ACA GAA TGC TGC AAA CTG ACC ACG CTG GAA CGT GGT CAA TGT ATA ATT CAT GCA GAA AAT (1001) 300

 301 asp glu lys pro glu gly leu ser pro asn leu asn arg phe leu gly asp arg asp phe asn gln phe ser ser gly glu lys asn ile
 GAT GAA AAA CCT GAA GGT CTA TCT CCA AAT CTA AAC AGG TTT TTA GGA GAT AGA GAT TTT AAC CAA TTT TCT TCA GGG GAA AAA AAT ATC (1091) 330

 331 leu ala ser phe val his glu tyr ser arg arg his pro gln leu ala val ser val ile leu arg val ala lys gly tyr gln glu
 TTC TTG GCA AGT TTT GTT CAT GAA TAT TCA AGA AGA CAT CCT CAG CTT GCT GTC TCA GTA ATT CTA AGA GTT GCT AAA GGA TAC CAG GAG (1181) 360

 361 leu glu lys cys phe gln thr glu asn pro leu glu cys gln asp lys gly glu glu leu gln lys tyr ile gln glu ser gln
 TTA TTG GAG AAG TGT TTC CAG ACT GAA AAC CCT CTT GAA TGC CAA GAT AAA GGA GAA GAA TTA CAG AAA TAC ATC CAG GAG AGC CAA (1271) 390

 391 ala leu ala lys arg ser cys gly leu phe gln lys leu gly glu tyr tyr leu gln asn ala phe leu val ala tyr thr lys lys ala
 GCA TTG GCA AAG CGA AGC TGC GGC CTC TTC CAG AAA CTA GGA GAA TAT TAC TTA CAA AAT GCG TTT CTC GTT TAC ACA AAG AAA GCC (1361) 420

 421 pro gln leu thr ser ser glu leu met ala ile thr arg lys met ala ala thr ala ala thr cys cys gln leu ser glu asp lys leu
 CCC CAG CTG ACC TCG TCG GAG CTG ATG GCC ATC ACC AGA AAA ATG GCA GCC ACA GCA GCC ACT TGT TGC CAA CTC AGT GAG GAC AAA CTA (1451) 450

Fig. 1 (CONTINUED)

3/4

451 leu ala cys gly glu gly ala ala asp ile ile ile gly his leu cys ile arg his glu met thr pro val asn pro gly val gly gln 470
 TTG GCC TGT GGC GAG GGA GCG GCT GAC ATT ATT ATC GGA CAC TTA TGT ATC AGA CAT GAA ATG ACT CCA GTA AAC CCT GGT GTT GGC CAG(1541) 480
 481 cys cys thr ser ser tyr ala asn arg arg pro cys phe ser ser leu val val asp glu thr tyr val pro pro ala phe ser asp asp 510
 TGC TGC ACT TCT TCA TAT GCC AAC AGG AGG CCA TGC TTC AGC AGC TTG GTG GAT GAA ACA TAT GTC CCT CCT GCA TTC TCT GAT GAC(1631)
 511 lys phe ile phe his lys asp leu cys gln ala gln gly val ala leu gln thr met lys gln glu phe leu ile asn leu val lys gln 540
 AAG TTC ATT TTC CAT AAG GAT CTG TGC CAA GCT CAG GGT GTA GCG CTG CAA ACG ATG AAG CAA GAG TTT CTC ATT AAC CTT GTG AAG CAA(1721)
 541 lys pro gln ile thr glu glu gln leu glu ala val ile ala asp phe ser gly leu leu glu lys cys cys gln gly gln glu gln glu 570
 AAG CCA CAA ATA ACA GAG GAA CAA CTT GAG GCT GTC ATT GCA GAT TTC TCA GGC CTG TTG GAG AAA TGC TGC CAA GGC CAG GAA CAG GAA(1811)
 571 val cys phe ala glu glu gly gln lys leu ile ser lys thr arg ala ala leu gly val ter 590
 GTC TGC TTT GCT GAA GAG GGA CAA AAA CTG ATT TCA AAA ACT CGT GCT GCT TTG GGA GTT TAA ATTACTTCAGGGGAGAGAGACAAACGAGTCT(1908)
 TTCATTCGGTGTGAACCTTTCTCTTTAATTTTAACGATTAACTTTTGTGAATTATGAATATGAAGACTTTTATGTGAGATTTCTTATCAGAGAAATATAAATAATCTCCAAA(2027)

Fig. 1 (CONTINUED)

4/4




Fig. 2

SEQUENCE LISTING

<110> Atlantic Biopharmaceuticals, Inc.
Murgita, Robert A.
Mulroy, Robert
Lindsay, Stace

<120> USE OF rAFP TO INHIBIT OR PREVENT
APOPTOSIS

<130> 06727/010W02

<150> US 60/152,166

<151> 1999-09-02

<160> 8

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2027

<212> DNA

<213> Homo sapiens

<400> 1

atattgtgct	tccaccactg	ccaataacaa	aataactagc	aaccatgaag	tgggtggaat	60
caattttttt	aatttttcta	ctaaatttta	ctgaatccag	aacactgcat	agaaatgaat	120
atggaatagc	ttccatattg	gattcttacc	aatgtactgc	agagataagt	ttagctgacc	180
tggctaccat	atTTTTtgcc	cagtttggtc	aagaagccac	ttacaaggaa	gtaagcaaaa	240
tggtgaaaga	tgcattgact	gcaattgaga	aaccctactg	agatgaacag	tcttcagggt	300
gtttagaaaa	ccagctacct	gcctttctgg	aagaactttg	ccatgagaaa	gaaattttgg	360
agaagtacgg	acattcagac	tgctgcagcc	aaagtgaaga	gggaagacat	aactgttttc	420
ttgcacacaa	aaagcccact	gcagcatgga	tcccactttt	ccaagttcca	gaacctgtca	480
caagctgtga	agcatatgaa	gaagacaggg	agacattcat	gaacaaattc	atztatgaga	540
tagcaagaag	gcatcccttc	ctgtatgcac	ctacaattct	tctttcggct	gctgggtatg	600
agaaaaataat	tccatcttgc	tgcaaagctg	aaaatgcagt	tgaatgcttc	caaacaaagg	660
cagcaacagt	tacaaaagaa	ttaagagaaa	gcagcttggt	aaatcaacat	gcatgtccag	720
taatgaaaaa	ttttgggacc	cgaactttcc	aagccataac	tgttactaaa	ctgagtcaga	780
agttttacca	agttaatttt	actgaaatcc	agaaactagt	cctggatgtg	gccccatgtac	840
atgagcactg	ttgcagagca	gatgtgctgg	attgtctgca	ggatggggaa	aaaatcatgt	900
cctacatatg	ttctcaacaa	gacactctgt	caaacaaaat	aacagaatgc	tgcaaactga	960
ccacgctgga	acgtgggtcaa	tgtataattc	atgcagaaaa	tgatgaaaaa	cctgaagggtc	1020
tatctccaaa	tctaaacagg	tttttagggag	atagagattt	taaccaattt	tcttcagggg	1080
aaaaaaatat	cttcttgcca	agttttgttc	atgaatatcc	aagaagacat	cctcagcttg	1140
ctgtctcagt	aattctaaga	gttgctaaag	gataccagga	gttattggag	aagtgtttcc	1200
agactgaaaa	ccctcttgaa	tgccaagata	aaggagaaga	agaattacag	aaatacatcc	1260
aggagagcca	agcattggca	aagcgaagct	gcggcctctt	ccagaaacta	ggagaatatt	1320
acttacaaaa	tgagttttct	gttgcttaca	caaagaaagc	ccccagctg	acctcgtcgg	1380
agctgatggc	catcaccaga	aaaatggcag	ccacagcagc	cacttggtgc	caactcagtg	1440
aggacaaact	attggcctgt	ggcgagggag	cggctgacat	tattatcgga	cacttatgta	1500
tcagacatga	aatgactcca	gtaaacctcg	gtggtggcca	gtgctgcact	tcttcatatg	1560
ccaacaggag	gccatgcttc	agcagcttgg	tgggtggatga	aacatatgtc	cctcctgcat	1620
tctctgatga	caagttcatt	ttccataagg	atctgtgcca	agctcagggt	gtagcgtctgc	1680

```

aaaggatgaa gcaagagttt ctcattaacc ttgtgaagca aaagccacaa ataacagagg 1740
aacaacttga ggctctcatt gcagatttct caggcctgtt ggagaaatgc tgccaaggcc 1800
aggaacagga agtctgcttt gctgaagagg gacaaaaact gattttcaaaa actggtgctg 1860
ctttgggagt ttaaattact tcaggggaag agaagacaaa acgagtcttt cattcggtgt 1920
gaacttttct ctttaatttt aactgattta acactttttg tgaattaatg aaatgataaa 1980
gacttttatg tgagatttcc ttatcacaga aataaaaat atctccaaa 2027

```

<210> 2

<211> 590

<212> PRT

<213> Homo sapiens

<400> 2

```

Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
1          5          10          15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
20          25          30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
35          40          45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
50          55          60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65          70          75          80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
85          90          95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
100          105          110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
115          120          125
Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
130          135          140
Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
145          150          155          160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
165          170          175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
180          185          190
Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
195          200          205
Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
210          215          220
Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val
225          230          235          240
Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
245          250          255
Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
260          265          270
Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
275          280          285
Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro
290          295          300
Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
305          310          315          320
Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val

```

```

          325          330          335
His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
          340          345          350
Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
          355          360          365
Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Leu Gln Lys
          370          375          380
Tyr Ile Gln Glu Ser Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe
385          390          395          400
Gln Lys Leu Gly Glu Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr
          405          410          415
Thr Lys Lys Ala Pro Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr
          420          425          430
Arg Lys Met Ala Ala Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp
          435          440          445
Lys Leu Leu Ala Cys Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His
          450          455          460
Leu Cys Ile Arg His Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln
465          470          475          480
Cys Cys Thr Ser Ser Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu
          485          490          495
Val Val Asp Glu Thr Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe
          500          505          510
Ile Phe His Lys Asp Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg
          515          520          525
Met Lys Gln Glu Phe Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile
          530          535          540
Thr Glu Glu Gln Leu Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu
545          550          555          560
Glu Lys Cys Cys Gln Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu
          565          570          575
Gly Gln Lys Leu Ile Ser Lys Thr Gly Ala Ala Leu Gly Val
          580          585          590

```

<210> 3
 <211> 197
 <212> PRT
 <213> Homo sapiens

```

<400> 3
Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
 1          5          10          15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
          20          25          30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
          35          40          45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
          50          55          60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65          70          75          80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
          85          90          95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro

```

```

                100                105                110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
                115                120                125
Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
                130                135                140

Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
145                150                155                160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
                165                170                175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
                180                185                190
Glu Leu Arg Glu Ser
                195

```

<210> 4
 <211> 192
 <212> PRT
 <213> Homo sapiens

```

<400> 4
Ser Leu Leu Asn Gln His Ala Cys Pro Val Met Lys Asn Phe Gly Thr
 1                5                10                15
Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu Ser Gln Lys Phe Thr
                20                25                30
Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val Leu Asp Val Ala His
                35                40                45
Val His Glu His Cys Cys Arg Ala Asp Val Leu Asp Cys Leu Gln Asp
                50                55                60
Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser
65                70                75                80
Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln
                85                90                95
Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro
                100                105                110
Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser
                115                120                125
Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg
                130                135                140
Arg His Pro Gln Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly
145                150                155                160
Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu
                165                170                175
Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser
                180                185                190

```

<210> 5
 <211> 201
 <212> PRT
 <213> Homo sapiens

<400> 5

Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
 1 5 10 15
 Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
 20 25 30
 Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
 35 40 45
 Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
 50 55 60
 Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
 65 70 75 80
 Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
 85 90 95
 Tyr Ala Asn Arg Arg Pro Cys Phe Ser Leu Val Val Asp Glu Thr
 100 105 110
 Tyr Val Pro Pro Ala Phe Ser Asp Lys Phe Ile Phe His Lys Asp
 115 120 125
 Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
 130 135 140
 Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu
 145 150 155 160
 Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
 165 170 175
 Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
 180 185 190
 Ser Lys Thr Gly Ala Ala Leu Gly Val
 195 200

<210> 6

<211> 389

<212> PRT

<213> Homo sapiens

<400> 6

Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
 1 5 10 15
 Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
 20 25 30
 Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
 35 40 45
 Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
 50 55 60
 Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
 65 70 75 80
 His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
 85 90 95
 Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
 100 105 110
 Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
 115 120 125
 Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
 130 135 140
 Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
 145 150 155 160

Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
 165 170 175
 Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
 180 185 190
 Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
 195 200 205
 Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
 210 215 220
 Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val
 225 230 235 240
 Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
 245 250 255
 Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
 260 265 270
 Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
 275 280 285
 Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro
 290 295 300
 Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
 305 310 315 320
 Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val
 325 330 335
 His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
 340 345 350
 Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
 355 360 365
 Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys
 370 375 380
 Tyr Ile Gln Glu Ser
 385

<210> 7

<211> 393

<212> PRT

<213> Homo sapiens

<400> 7

Ser Leu Leu Asn Gln His Ala Cys Pro Val Met Lys Asn Phe Gly Thr
 1 5 10 15
 Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu Ser Gln Lys Phe Thr
 20 25 30
 Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val Leu Asp Val Ala His
 35 40 45
 Val His Glu His Cys Cys Arg Ala Asp Val Leu Asp Cys Leu Gln Asp
 50 55 60
 Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser
 65 70 75 80
 Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln
 85 90 95
 Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro
 100 105 110
 Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser
 115 120 125

Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg
 130 135 140
 Arg His Pro Gln Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly
 145 150 155 160
 Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu
 165 170 175
 Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser
 180 185 190
 Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
 195 200 205
 Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
 210 215 220
 Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
 225 230 235 240
 Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
 245 250 255
 Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
 260 265 270
 Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
 275 280 285
 Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr
 290 295 300
 Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp
 305 310 315 320
 Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
 325 330 335
 Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu
 340 345 350
 Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
 355 360 365
 Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
 370 375 380
 Ser Lys Thr Gly Ala Ala Leu Gly Val
 385 390

<210> 8

<211> 325

<212> PRT

<213> Homo sapiens

<400> 8

Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser Asn Lys Ile Thr
 1 5 10 15
 Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln Cys Ile Ile His
 20 25 30
 Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro Asn Leu Asn Arg
 35 40 45
 Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser Gly Glu Lys Asn
 50 55 60
 Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg Arg His Pro Gln
 65 70 75 80
 Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly Tyr Gln Glu Leu
 85 90 95

-8-